Matthias Höllerhage

Dr. Matthias Höllerhage

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GGGoutham K. Ganjam
Goutham K. Ganjam
KBKathrin Bolte
Kathrin Bolte
LMLina A. Matschke
Lina A. Matschke
SNSandra Neitemeier
Sandra Neitemeier
ADAmalia Dolga
Amalia Dolga
CCCarsten Culmsee
Carsten Culmsee
Evolving concepts on Parkinson’s disease (PD) pathology suggest that α-synuclein (aSYN) promote dopaminergic neuron dysfunction and death through accumulating in the mitochondria. However, the consequence of mitochondrial aSYN localisation on mitochondrial structure and bioenergetic functions in neuronal cells are poorly understood. Therefore, we investigated deleterious effects of mitochondria-targeted aSYN in differentiated human dopaminergic neurons in comparison with wild-type (WT) aSYN overexpression and corresponding EGFP (enhanced green fluorescent protein)-expressing controls. Mitochondria-targeted aSYN enhanced mitochondrial reactive oxygen species (ROS) formation, reduced ATP levels and showed severely disrupted structure and function of the dendritic neural network, preceding neuronal death. Transmission electron microscopy illustrated distorted cristae and many fragmented mitochondria in response to WT-aSYN overexpression, and a complete loss of cristae structure and massively swollen mitochondria in neurons expressing mitochondria-targeted aSYN. Further, the analysis of mitochondrial bioenergetics in differentiated dopaminergic neurons, expressing WT or mitochondria-targeted aSYN, elicited a pronounced impairment of mitochondrial respiration. In a pharmacological compound screening, we found that the pan-caspase inhibitors QVD and zVAD-FMK, and a specific caspase-1 inhibitor significantly prevented aSYN-induced cell death. In addition, the caspase inhibitor QVD preserved mitochondrial function and neuronal network activity in the human dopaminergic neurons overexpressing aSYN. Overall, our findings indicated therapeutic effects by caspase-1 inhibition despite aSYN-mediated alterations in mitochondrial morphology and function.

17 September 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
QTQilin Tang
Qilin Tang
PGPan Gao
Pan Gao
TAThomas Arzberger
Thomas Arzberger
MHMatthias Höllerhage
Matthias Höllerhage
JHJochen Herms
Jochen Herms
TKThomas Koeglsperger
Thomas Koeglsperger
Dopaminergic (DA) cell death in Parkinson’s disease (PD) is associated with the gradual appearance of neuronal protein aggregates termed Lewy bodies (LBs) that are comprised of vesicular membrane structures and dysmorphic organelles in conjunction with the protein alpha-Synuclein (α-Syn). Although the exact mechanism of neuronal aggregate formation and death remains elusive, recent research suggests α-Syn-mediated alterations in the lysosomal degradation of aggregated proteins and organelles – a process termed autophagy. Here, we used a combination of molecular biology and immunochemistry to investigate the effect of α-Syn on autophagy turnover in cultured human DA neurons and in human post-mortem brain tissue. We found α-Syn overexpression to reduce autophagy turnover by compromising the fusion of autophagosomes with lysosomes, thus leading to a decrease in the formation of autolysosomes. In accord with a compensatory increase in the plasma membrane fusion of autophagosomes, α-Syn enhanced the number of extracellular vesicles (EV) and the abundance of autophagy-associated proteins in these EVs. Mechanistically, α-Syn decreased the abundance of the v-SNARE protein SNAP29, a member of the SNARE complex mediating autophagolysosome fusion. In line, SNAP29 knockdown mimicked the effect of α-Syn on autophagy whereas SNAP29 co-expression reversed the α-Syn-induced changes on autophagy turnover and EV release and ameliorated DA neuronal cell death. In accord with our results from cultured neurons, we found a stage-dependent reduction of SNAP29 in SNc DA neurons from human post-mortem brain tissue of Lewy body pathology (LBP) cases. In summary, our results thus demonstrate a previously unknown effect of α-Syn on intracellular autophagy-associated SNARE proteins and, as a consequence, a reduced autolysosome fusion. As such, our findings will therefore support the investigation of autophagy-associated pathological changes in PD

13 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMatthias Höllerhage
Matthias Höllerhage
CMClaudia Moebius
Claudia Moebius
JMJohannes Melms
Johannes Melms
WCWei-Hua Chiu
Wei-Hua Chiu
JGJoachim N. Goebel
Joachim N. Goebel
GHGünter U. Höglinger
Günter U. Höglinger
α-synuclein-induced neurotoxicity is a core pathogenic event in neurodegenerative synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy. There is currently no disease-modifying therapy available for these diseases. We screened 1,600 FDA-approved drugs for their efficacy to protect LUHMES cells from degeneration induced by wild-type α-synuclein and identified dipyridamole, a non-selective phosphodiesterase inhibitor, as top hit. Systematic analysis of other phosphodiesterase inhibitors identified a specific phosphodiesterase 1 inhibitor as most potent to rescue from α-synuclein toxicity. Protection was mediated by an increase of cGMP and associated with the reduction of a specific α-synuclein oligomeric species. RNA interference experiments confirmed PDE1A and to a smaller extent PDE1C as molecular targets accounting for the protective efficacy. PDE1 inhibition also rescued dopaminergic neurons from wild-type α-synuclein induced degeneration in the substantia nigra of mice. In conclusion, this work identifies inhibition of PDE1A in particular as promising target for neuroprotective treatment of synucleinopathies.

3 February 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TCTasnim Chakroun
Tasnim Chakroun
VEValentin Evsyukov
Valentin Evsyukov
NNNiko-Petteri Nykänen
Niko-Petteri Nykänen
MHMatthias Höllerhage
Matthias Höllerhage
ASAndreas Schmidt
Andreas Schmidt
GHGünter U. Höglinger
Günter U. Höglinger
Aggregation of alpha-synuclein (αSyn) is a crucial event underlying the pathophysiology of synucleinopathies. The existence of various intracellular and extracellular αSyn species, including cleaved αSyn, complicates the quest for an appropriate therapeutic target. Hence, to develop efficient disease-modifying strategies, it is fundamental to achieve a deeper understanding of the relevant spreading and toxic αSyn species. Here, we describe comparative and proof-of-principle approaches to determine the involvement of αSyn fragments in intercellular spreading. We demonstrate that two different αSyn fragments (1–95 and 61–140) fulfill the criteria of spreading species. They efficiently instigate formation of proteinase-K-resistant aggregates from cell-endogenous full-length αSyn, and drive it into different aggregation pathways. The resulting aggregates induce cellular toxicity. Strikingly, these aggregates are only detectable by specific antibodies. Our results suggest that αSyn fragments might be relevant not only for spreading, but also for aggregation-fate determination and differential strain formation.

1 September 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
CNCarmen Noelker
Carmen Noelker
LLLixia Lu
Lixia Lu
MHMatthias Höllerhage
Matthias Höllerhage
FVFranca Vulinovic
Franca Vulinovic
ASAnnekathrin Sturn
Annekathrin Sturn
HAHartmann Andreas
Hartmann Andreas

1 May 2019 in Neuropharmacology
Verified
Journal Article
Closed access
MHMatthias Höllerhage
Matthias Höllerhage
NFNatascha Fussi
Natascha Fussi
TRThomas W. Rösler
Thomas W. Rösler
WWWolfgang Wurst
Wolfgang Wurst
CBChristian Behrends
Christian Behrends
GHGünter U. Höglinger
Günter U. Höglinger